Pompe Disease: Opportunity Analysis and Forecasts to 2027

2018-11-27
Price :
Published : Nov-2018
No. of Pages : 86

Pompe Disease: Opportunity Analysis and Forecasts to 2027

Summary

Pompe disease (PD) is a rare genetic disorder resulting in the accumulation of glycogen with lysosomes in various tissues of the body. It is caused by a multitude of different phenotypical mutations to the GAA gene which is responsible for the transcription of ?-glucosidase. ?-glucosidase is responsible for glycogen degradation through enzymatic cleavage. PD is characterized by two types: infantile-onset Pomp disease (IOPD) and late-onset Pompe disease (LOPD). IOPD tends to be caused a severe deficiency or entire absence of GAA, resulting in symptoms being apparent from birth. Sufferers of IOPD tend to not reach their second birthday. LOPD has a large spectrum of severity, with symptoms manifesting typically in early adulthood. Sufferers have known to live a full life span if diagnosed early and given enzyme replacement therapy (ERT) to slow the progression of the disease.

GlobalData estimates the 2017 sales for the PD market at approximately $684 million across the 8MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), Brazil and Japan. By 2027 GlobalData expects the overall market to grow at a moderate compound annual growth rate (CAGR) of 2.8% to reach sales of $903 million over the 10-year period. The US market is anticipated to grow the fastest of the three regions, recording a CAGR of 4.9%, while the 5EU and Japan will each record CAGRs of 1.2% and 0.6%, respectively. At the end of 2027, the US will contribute around 51.9% of global sales, while the 5EU and Japan will account for 35.7% and 10.3% of global sales, respectively. The higher sales numbers for the US can be attributed to the higher price of pharmaceuticals and the greater diagnosed prevalence of PD.

Key Questions Answered

– ERT therapies are currently the cornerstone of PD treatment. Patients typically receive therapy from diagnosis to receive reduce glycogen accumulation. Nevertheless, ERT therapy cannot cross the blood brain barrier causing inevitable deterioration of the CNS resulting in death. Because of this, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the PD market with novel mechanisms of action?
– The current late-stage PD pipeline encompasses one additional ERT therapy being development by the current market drug owners Sanofi Genzyme. Will the late-stage drug make a significant impact on the PD market? Will this late-stage developmental drug capture a share of the PD market? and why?

Scope

– Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized PD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market.
– Overview of pulmonary arterial hypertension, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized PD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global PD therapeutics market from 2017-2027.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q2 2019

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informatio......
$1500

Prostate Cancer: Epidemiology Forecast to 2028

Prostate Cancer: Epidemiology Forecast to 2028 Summary Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.2 million men were diagnosed with prostate cancer in 2018 (International Agency for Research on Cancer, 2019). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2019a). Changes in PSA testing and screenin......
$3995

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028

Spinal Muscular Atrophy: Epidemiology Forecast in Asia-Pacific Markets to 2028 Summary Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved (Amico et al., 2011). Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset (Finkel et al., 2015). In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA (Verhaart, Robertson, Wilson, et al., 2017). GlobalData epide......
$3495

Wearable Technology in Healthcare – Thematic Research

Wearable Technology in Healthcare - Thematic Research Summary Wearables have the potential to transform healthcare through the ability to remotely measure and analyse patient data in real-time. In addition to health and wellness, they have their greatest potential in healthcare to address spiralling healthcare costs, aging populations, and the burden of chronic disease across the globe. The integration of wearable tech with augmented reality (AR), Big Data, artificial intelligence (AI), and cloud computing solutions, as well as the falling prices of sensors, open-source application programming interfaces (APIs), frameworks, and libraries, is enabling faster and more cost-effective solutions within the Internet of Things (IoT) ecosystem. This report provides an assessment of the key techn......
$1950

PharmSource – Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition

PharmSource - Contract Small Molecule API Manufacturing Industry by the Numbers - 2019 Edition Summary This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry. Scope Who should buy this report? - This 44-page report gives important, expert insight you won't find in any other source. 26 tables and figures ......
$4995

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inform......
$1000

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for June 2019 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides inf......
$1000

Respiratory Syncytial Virus: Epidemiology Forecast to 2028

Respiratory Syncytial Virus: Epidemiology Forecast to 2028 Summary Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries. RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one o......
$3995

Ovarian Cancer: Epidemiology Forecast to 2028

Ovarian Cancer: Epidemiology Forecast to 2028 Summary Ovarian cancer is the most lethal gynecologic cancer and overall a leading cause of cancer incidence and mortality worldwide. The disease is defined as uncontrolled cell growth in the ovaries, although research has shown that the disease may actually originate in the fallopian tubes. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the observed survival rates to calculate the five-year diagnosed prevalent cases, taking into account the significant relationship between age and ovarian cancer incidence, survival, and prevalence. GlobalData epidemiologists applied country-specific incidence rates of ovarian cancer, wherever available, to each country's pop......
$3995

Alopecia Areata: Epidemiology Forecast to 2028

Alopecia Areata: Epidemiology Forecast to 2028 Summary Alopecia areata (AA) is a common, clinically heterogeneous, immune-mediated and a non-scarring hair loss disorder (Hordinsky, 2013). It typically presents with sharply demarcated round patches of hair loss and may present at any age. Experimental and clinical evidence suggests that AA is caused by autoimmune attack against the hair follicles. The precise path mechanism, however, remains unknown (Dainichi and Kabashima, 2017). GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the diagnosed incident and prevalent cases of AA in the 7MM. GlobalData epidemiologists applied country-specific incidence and prevalence rates of AA, wherever available, to each country's......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy